# Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency

> **NCT02937454** · PHASE4 · COMPLETED · sponsor: **Vifor (International) Inc.** · enrollment: 1132 (actual)

## Conditions studied

- Iron Deficiency
- Heart Failure

## Interventions

- **DRUG:** ferric carboxymaltose
- **OTHER:** Normal saline 0.9%

## Key facts

- **NCT ID:** NCT02937454
- **Lead sponsor:** Vifor (International) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-03
- **Primary completion:** 2020-07-21
- **Final completion:** 2020-07-21
- **Target enrollment:** 1132 (ACTUAL)
- **Last updated:** 2021-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937454, "Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02937454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*